BioPharmaceuticals Market Access and Pricing, AstraZeneca, 200 Orchard Ridge Dr, Gaithersburg, MD, 20878, USA.
BioPharmaceuticals Medical, AstraZeneca, 200 Orchard Ridge Dr, Gaithersburg, MD, 20878, USA.
BMC Gastroenterol. 2024 Aug 3;24(1):246. doi: 10.1186/s12876-024-03334-4.
Eosinophilic esophagitis is a chronic inflammatory disorder of the esophagus. This real-world study used patient and physician surveys to describe the clinical characteristics and disease burden of eosinophilic esophagitis-overall and in a subgroup of patients with dysphagia despite treatment.
Data analyzed in this study were collected in 2020 from US and EU patients with eosinophilic esophagitis. Eligible patients were aged ≥ 12 years with a diagnosis of eosinophilic esophagitis, had an esophageal count of ≥ 15 eosinophils/high-power field at diagnosis, and were currently prescribed treatment for eosinophilic esophagitis.
Overall, 1001 patients were included, of whom 356 (36%) had dysphagia despite treatment. Demographics and clinical characteristics were similar in both populations. The severity of eosinophilic esophagitis was mild in more patients overall (69%) versus those with dysphagia despite treatment (48%). Patient disease history was similar in both populations, with some exceptions: common patient-reported symptoms were dysphagia (70% and 86%) and heartburn/acid reflux (55% and 49%), and common physician-reported symptoms were dysphagia (75% and 91%) and food impaction (46% and 52%). Treatment history was similar in both populations; overall, the most common treatments were proton pump inhibitors (83%) and topical corticosteroids (51%). Patients reported slightly more days with symptoms, higher impacts on activities of daily living, and slightly higher anxiety or depression in the dysphagia-despite-treatment population versus the overall population.
Eosinophilic esophagitis presents severe symptoms and comorbidities that substantially impact patients' well-being and quality of life. Greater awareness of and novel treatments for eosinophilic esophagitis are needed.
嗜酸性粒细胞性食管炎是一种慢性食管炎症性疾病。本真实世界研究通过患者和医生调查,描述了嗜酸性粒细胞性食管炎的临床特征和疾病负担——总体情况以及在经过治疗仍有吞咽困难的患者亚组中。
本研究分析的数据来自于 2020 年美国和欧盟的嗜酸性粒细胞性食管炎患者。符合条件的患者年龄≥12 岁,诊断为嗜酸性粒细胞性食管炎,在诊断时食管计数≥15 个嗜酸性粒细胞/高倍视野,并且目前正在接受嗜酸性粒细胞性食管炎的治疗。
总体而言,纳入了 1001 名患者,其中 356 名(36%)经治疗后仍有吞咽困难。这两个人群的人口统计学和临床特征相似。在总体人群中,更多的患者的嗜酸性粒细胞性食管炎严重程度较轻(69%),而经治疗后仍有吞咽困难的患者严重程度较轻(48%)。两个人群的患者疾病史相似,但也存在一些差异:常见的患者报告症状为吞咽困难(70%和 86%)和烧心/胃酸反流(55%和 49%),常见的医生报告症状为吞咽困难(75%和 91%)和食物嵌塞(46%和 52%)。两个人群的治疗史相似;总体而言,最常见的治疗方法是质子泵抑制剂(83%)和局部皮质类固醇(51%)。与总体人群相比,经治疗后仍有吞咽困难的患者报告有更多的症状日数、对日常生活活动的影响更大,并且焦虑或抑郁程度略高。
嗜酸性粒细胞性食管炎表现出严重的症状和合并症,这些症状和合并症极大地影响了患者的幸福感和生活质量。需要提高对嗜酸性粒细胞性食管炎的认识并开发新的治疗方法。